Needham & Company analyst, Danielle Brille, reiterated her Buy rating on shares of Sage Therapeutics (NASDAQ: SAGE) after hosting a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE